InvestorsHub Logo
Followers 15
Posts 524
Boards Moderated 0
Alias Born 12/28/2009

Re: Vanilla Fitbit post# 39173

Sunday, 05/02/2021 4:10:58 AM

Sunday, May 02, 2021 4:10:58 AM

Post# of 44690
Who or what is NeuroRX?
Let's NeuroRX answer that for itself.
The company is also featured in their monthly PR.

The evolution of a small pharmaceutical company:
About NeuroRX (December 7, 2021)
NeuroRX has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop a drug for suicidal bipolar depression called NRX-101, currently in Phase 3 trials. Its work with RLF-100 (licensed from Relief Therapeutics) was originally considered for treatment of erectile dysfunction. The U.S. and Israeli-based biotech NeuroRX owns the rights to the drug in the United States. The U.S. FDA granted a fest-track designation to RLF-100 for treatment of respiratory distress in COVID-19. By September, 2020 NeuroRX submitted a request for Emergency Use Authorization in the USA for its use in patients in intensive care.

About NeuroRX (April 7, 2021)
NeuroRX draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRX has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer’s Neuroscience and Pain Division. NeuroRX recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp (NASDAQ:BRPA) (“BRPA”), and intends to apply for listing on the NASDAQ under the proposed symbol “NRXP”.

Reported May 1, 2021
Strategically Situated Georgia Links Deal with NeuroRX for Access to ZYESAMI: Lawsuits Most Certainly Imminent

Unfortunately, nowhere is stated where the funds for the development of various drugs came from. Larger investors may also be involved, but IMO they must have made the money selflessly available. It's a miracle that something like this still exists today.